Core Insights - Pfizer's stock has experienced a decline of 9.90% over the past month, following a gain of 10.02% the previous month, resulting in a year-to-date loss of 7.33% and an annual decline of 11.17% [3] - The recent drop in stock price is attributed to the FDA's recommendation limiting COVID-19 vaccines to seniors and certain medical conditions, which poses a challenge for Pfizer's COVID-related revenue [4] - Pfizer's total revenues for FY 2025 are forecasted to be between $61 billion and $64 billion, with oncology sales expected to grow significantly [5] Financial Performance - Pfizer's revenue from COVID products, including Paxlovid and Comirnaty, was $11.1 billion in 2024, but the company is now focusing on non-COVID products to stabilize revenue [4][10] - The company reported a significant drop in stock price, down 20.85% over the past five years and more than 54% since its all-time high in December 2021 [6] - Pfizer's revenue and net income figures from 2015 to 2024 show fluctuations, with a peak revenue of $100.33 billion in 2022 and a net income of $31.37 billion [9] Market Outlook - Analysts project a one-year price target for Pfizer at $28.60, indicating a potential upside of 15.97% from the current share price, with a longer-term forecast of $33.60 by the end of 2025 [12] - The oncology drug market is expected to grow at an 8.1% CAGR from 2025 to 2030, which could benefit Pfizer as it reallocates resources towards this segment [10] - The obesity drug market is forecasted to expand at a 22.3% CAGR from 2025 to 2030, with Pfizer developing a new oral formulation to compete in this space [10] Strategic Partnerships - Pfizer's collaboration with Bristol Myers Squibb on the blood thinner Eliquis generated $1.83 billion in Q4 2024, marking a 14% year-over-year increase [11] - The anticoagulant market, valued at $34.8 billion in 2023, is projected to grow at a 10.2% CAGR from 2024 to 2030, presenting further opportunities for Pfizer [11]

Group 1: Pfizer - Pfizer's stock has decreased by approximately 62% from its pandemic highs, yet it offers a high dividend yield of 7.3% [4] - The company's adjusted earnings per share fell from $6.58 in 2022 to $3.11 last year due to declining demand for COVID-19 vaccines and treatments [4][5] - Pfizer anticipates a 6.8% decline in adjusted earnings for the current year, with a projected low of $2.80 per share, which is sufficient to support its annual dividend of $1.72 [5] - The drug Eliquis, which accounts for 14% of Pfizer's revenue, is expected to face competition from generics starting in 2028 [6] - Despite facing patent cliffs, Pfizer has a strong development pipeline, with over a dozen FDA approvals last year, indicating potential for continued dividend growth [7] Group 2: Prologis - Prologis has capitalized on the surge in e-commerce demand, becoming the largest real estate investment trust (REIT) available to everyday investors [8] - The stock has declined by about 12% from its March peak, currently offering a 3.7% yield [8] - Prologis has increased its dividend by 11.7% annually over the past five years, suggesting potential for double-digit yield on cost for investors in less than a decade [9] - Major customers include Amazon, Home Depot, and FedEx, but these tenants only account for 8.2% of total rent payments, showcasing strong diversification [9] - Prologis holds an A2 rating from Moody's and an A rating from S&P Global, with a low average interest rate of 3.1% on its debts [10] - The company can offer competitive rates to smaller competitors and is positioned for continued growth by acquiring and leasing back logistics real estate [11] Group 3: Investment Comparison - Pfizer offers a nearly double yield compared to Prologis, but its dividend growth rate is less than half that of Prologis [12] - For investors nearing retirement, Pfizer may be appealing, while Prologis is suggested as a better option for income-seeking investors [12]